FDA Approves Qulipta (atogepant) Oral CGRP Receptor Antagonist for the Preventive Treatment of Migraine

By | October 7, 2021
0 Comment

[unable to retrieve full-text content]NORTH CHICAGO, Ill., Sept. 28, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved Qulipta (atogepant) for the preventive treatment of episodic migraine in adults.1 Qulipta is the first…
Drugs.com – New Drug Approvals

Read More:  COVID-19: The Africa Medical Supplies Platform, Africa's united continental supply chain response to COVID, expands to African hospitals and CARICOM countries, and secures lifesaving COVID-19 medical treatment to benefit nearly 1 million Africans